ZLAB - ザイ・ラボ (Zai Lab Limited) ザイ・ラボ

 ZLABのチャート


 ZLABの企業情報

symbol ZLAB
会社名 Zai Lab Ltd (ザイ・ラボ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Zai Lab Ltd incorporated on March 28 2017 is a biopharmaceutical company. The Company is focused on discovering or licensing developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market including in the fields of oncology autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306) Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101) ZL-2302 and ZL-1101.   ザイ・ラボはケイマン諸島籍のバイオ医薬品企業。主に腫瘍、自己免疫、感染症の治療に向けた医薬品の開発・商業化に従事する。同社はTesaro社と共同で、経口タイプの上皮卵巣がんの治療薬「Zejula」を米国で販売する。中国市場において医療ニ―ズの高い分野で治療法の発見やライセンス供与に取り組む。本社は中国上海市。   Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.
本社所在地 4560 Jinke Road Bldg. 1 Fourth Floor Pudong Shanghai 201210 CHN
代表者氏名
代表者役職名
電話番号 +86 21-6163-2588
設立年月日 41334
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 88人
url www.zailaboratory.com
nasdaq_url https://www.nasdaq.com/symbol/zlab
adr_tso 11562969
EBITDA EBITDA(百万ドル) -67.07543
終値(lastsale) 17.41
時価総額(marketcap) 201311290.29
時価総額 時価総額(百万ドル) 868.68320
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 691.72338
当期純利益 当期純利益(百万ドル) -67.45513
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Zai Lab Ltd revenues was not reported. Net loss totaled to $41.5M. Results are not comparable due to year end change.

 ZLABのテクニカル分析


 ZLABのニュース

   Should You Already Consider Disposing Your Zai Lab (ZLAB) Shares?  2022/04/06 14:05:49 Insider Monkey
ClearBridge Investments, an investment management firm, published its “International Growth ACWI ex-U.S. Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
   ZLAB EQUITY NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB  2022/04/05 23:45:00 GlobeNewswire
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public.
   ZLAB INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB  2022/04/04 20:20:00 PR Newswire
NEW YORK , April 4, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially…
   INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm  2022/04/04 14:56:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
   After A 7.47% Jump In The Last Week, Does Zai Lab Limited (NASDAQ: ZLAB) Still Make Sense To Buy?  2022/04/02 13:30:00 Marketing Sentinel
During the last session, Zai Lab Limited (NASDAQ:ZLAB)’s traded shares were 0.5 million, with the beta value of the company hitting 1.21. At the end of the trading day, the stock’s price was $45.47, reflecting an intraday gain of 3.39% or $1.49. The 52-week high for the ZLAB share is $181.92, that puts it down … After A 7.47% Jump In The Last Week, Does Zai Lab Limited (NASDAQ: ZLAB) Still Make Sense To Buy? Read More »
   Zai Lab (ZLAB) to Release Quarterly Earnings on Tuesday  2021/11/08 09:36:41 Dakota Financial News
Zai Lab (NASDAQ:ZLAB) will be announcing its earnings results after the market closes on Tuesday, November 9th. Analysts expect the company to announce earnings of ($1.24) per share for the quarter. Investors interested in participating in the companys conference call can do so using this link. Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data []
   Zai Lab Limited: A Best Price-Positioned Biotech Stock, As Seen By Market-Makers  2021/11/07 04:50:17 Seeking Alpha
   Squarepoint Ops LLC Has $3.32 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)  2021/11/04 14:42:43 Transcript Daily
Squarepoint Ops LLC boosted its stake in shares of Zai Lab Limited (NASDAQ:ZLAB) by 292.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,782 shares of the companys stock after buying an additional 14,001 shares during the period. Squarepoint Ops LLCs holdings in Zai Lab were []
   Zai Lab Announces Upcoming Presentations in November Investor Conferences  2021/11/04 11:30:00 Intrado Digital Media
SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in November:
   Zai Lab Limited (NASDAQ:ZLAB) Position Reduced by FORA Capital LLC  2021/11/03 12:48:43 Dakota Financial News
FORA Capital LLC trimmed its stake in shares of Zai Lab Limited (NASDAQ:ZLAB) by 78.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 873 shares of the companys stock after selling 3,232 shares during the quarter. FORA Capital LLCs holdings in Zai Lab []
   Zai Lab's mid-stage lung cancer study doses first patient in China  2021/05/28 11:41:12 Seeking Alpha
   Bitcoin Forecast: Building a Base into Holiday Weekend - 28 May 2021  2021/05/28 08:57:44 DailyForex
Bitcoin continues to sit just above the 200 day EMA, as we are looking at the 40,000 level through the prism of resistance.
   Bitcoin falls back below $40,000 as cryptos plunge yet again - Yahoo Finance  2021/05/28 08:45:26 Yahoo Finance
Bitcoin falls back below $40,000 as cryptos plunge yet again Yahoo Finance
   Bitcoin price slides along with other cryptocurrencies - Fox Business  2021/05/28 08:37:12 Fox Business
Bitcoin price slides along with other cryptocurrencies Fox Business
   Here’s one thing Jefferies' Chris Wood doesn’t want crypto investors to do  2021/05/28 07:41:00 Economic Times India
Bitcoin, Dogecoin and Ethereums over 50 per cent collapse from their all-time highs sent shockwaves throughout the financial markets.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ザイ・ラボ ZLAB Zai Lab Limited)

 twitter  (公式ツイッターやCEOツイッターなど)